Track topics on Twitter Track topics that are important to you
Teva announced last week that it had reached an agreement to sell Paragard, an intrauterine copper contraceptive, to CooperSurgical for $1.1 billion and it has now announced the sale of the rest of the unit for $1.38 billion. The sales confirm Teva’s commitment to raising $2 billion to manage its debt payments by the end of the year.
Original Article: Teva completes sale of women’s health for $1.38 billionNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...